Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 3, 2012, Pages 1200-1207

  Leborgne, Felix ^a   Fowler, Jack ^b   Leborgne, José H ^a   Mezzera, Julieta ^a  

^a Hospital Italiano Montevideo   (Uruguay)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

ratio; Hypofractionated fractionation; Late complications; Prostate cancer; Radiotherapy

Indexed keywords

CONFIDENCE INTERVAL; CONFIDENCE LIMIT; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HYPOFRACTIONATION; LATE COMPLICATIONS; LOCALIZED PROSTATE CANCER; META ANALYSIS; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN;

DISEASES; PATIENT MONITORING; RADIOTHERAPY; STANDARDS;

THREE DIMENSIONAL;

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BLADDER STONE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HEMATURIA; HIGH RISK POPULATION; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; TRANSURETHRAL RESECTION; URINARY TRACT OBSTRUCTION;

AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; DOSE FRACTIONATION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RECTUM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856398974     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.12.040     Document Type: Article

References (46)

1. F. Leborgne, and J.F. Fowler Late outcomes following hypofractionated conformal radiotherapy for localized prostate cancer: A nonrandomized contemporary comparison Int J Radiat Oncol Biol Phys 74 2009 1441 1446
2. R.C. Urtasun, and J.F. Fowler Dr. Felix Leborgne, 1935-2009 Int J Radiat Oncol Biol Phys 75 2009 1288 1289
3. F. Leborgne, and J.F. Fowler Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: Nonrandomized contemporary comparison with standard fractionation Int J Radiat Oncol Biol Phys 72 2008 770 776
4. L.L. Kestin, N.S. Goldstein, and F.A. Vicini Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54 2002 680 697
5. D.B. Chism, E.M. Horwitz, and A.L. Hanlon Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement Int J Radiat Oncol Biol Phys 55 2003 71 77
6. E.H. Huang, A. Pollack, and L. Levy Tate rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 54 2002 1314 1321
7. S.T.H. Peeters, J.V. Lebesque, and W.D. Heemsbergen Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 64 2006 1151 1161
8. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
9. J.F. Fowler The linear-quadratic formula and progress in fractionated radiotherapy Br J Radiol 62 1989 679 694
10. J.F. Fowler 21 Years of biologically effective dose: A review Br J Radiol 83 2010 554 568
11. P. Diez, I.S. Vogelius, and S.M. Bentzen A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer Int J Radiat Oncol Biol Phys 77 2010 1066 1071
12. K. Diem Binomial Exact Confidence Limits. Documenta Geigy Scientific Tables 6th ed 1962 Geigy Pharmaceutical Manchester, UK 99 100
13. S.M. Bentzen, and M.A. Ritter The α/β ratio for prostate cancer: What is it, really? Radiother Oncol 76 2005 1 3
14. H. Lukka, C. Hayter, and P. Warde A randomized trial comparing two fractionation schedules for patients with localized prostate cancer Radiother Oncol 69 2003 57
15. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6123 6138
16. R. Valdagni, C. Italia, and P. Montanaro Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiotherapy Radiother Oncol 75 2005 74 82
17. A. Dasu Is the α/β value for prostate tumors low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol UK) 19 2007 289 301
18. S.G. Williams, J.M.G. Taylor, and N.G. Liu Use of individual fraction size data from 3756 patients to directly determine the α/β ratio of prostate cancer Int J Radiat Oncol Biol Phys 64 2007 24 33
19. C. Proust-Lima, J.M.G. Taylor, and S Sécher Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics Int J Radiat Oncol Biol Phys 79 2010 195 201
20. R. Miralbell, S.A. Roberts, and E. Zubizarreta Dose-fractionation radiosensitivity of prostate cancer deduced from radiotherapy outcome of 5969 patients in seven international institutional datasets Int J Radiat Oncol Biol Phys 75 2009 S81
21. H.D. Thames, D. Kuban, and L.B. Levy The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated with between 1987 and 1995 Radiother Oncol 96 2010 6 12
22. S.A. Roberts, and J.H. Hendry Time factors in larynx tumor radiotherapy: Lag times and intertumor heterogeneity in clinical datasets from four centers Int J Radiat Oncol Biol 45 1999 1247 1257
23. A.J. van der Kogel Radiation response and tolerance of normal tissues G.G. Steel, Basic Clinical Radiobiology 2002 Arnold London 30 41
24. A. Jackson, M.W. Skwarchuk, and M.J. Zelefsky Late rectal bleeding after conformal radiotherapy of prostate cancer (2): Volume effects and dose-volume histograms Int J Radiat Oncol Biol Phys 49 2001 685 698
25. C. Vargas, A Martinez, and L.L. Kestin Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy Int J Radiat Oncol Biol Phys 62 2005 1297 1308
26. T. Akimoto, H. Katoh, and Y. Kitamoto Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: Impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding Int J Radiat Oncol Biol Phys 65 2006 364 370
27. M. Stasi, F. Munoz, and C. Fiorino Emptying the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer Radiother Oncol 80 2006 363 370
28. W.D. Heemsbergen, S.T.H. Peeters, and P.C.M. Koper Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: Consequential late damage Int J Radiat Oncol Biol Phys 66 2006 3 10
29. C. Luo, C.C. Yang, and S. Narayan Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer Int J Radiat Oncol Biol Phys 66 2006 1253 1262
30. V. Vavassori, C. Fiorino, and T. Rancati Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose and 3D-CRT: Results of a prospective multicenter study Int J Radiat Oncol Biol Phys 67 2007 1401 1410
31. S. Marzi, G. Arcangeli, and B. Saracino Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer Int J Radiat Oncol Biol Phys 68 2007 41 49
32. J.A. Cesaretti, R.G. Stock, and D.P. Atencio A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy Int J Radiat Oncol Biol Phys 68 2007 230 239
33. M. Soehn, M. Alber, and D. Yan Principal component analysis-based pattern analysis of dose-volume histograms and influence on rectal toxicity Int J Radiat Oncol Biol Phys 69 2007 230 239
34. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
35. L.W. Chan, P. Xia, and A.R. Gottschalk Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 69 77
36. M. Soehn, C. Vargas, and D. Yan Quantitative modeling of the incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using EUD- and dose-volume based NTCP models Radiother Oncol 81 2008 S203 S204
37. L. Strigari, G. Arcangeli, and S. Arcangeli Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1454 1460
38. A.M. Henry, B. Al-Qaisieh, and K. Gould Outcomes following iodine-125 monotherapy for localized prostate cancer: The results of leeds 10-year single-center brachytherapy experience Int J Radiat Oncol Biol Phys 76 2010 50 56
39. A.M. Nichol, P.R. Warde, and G.A. Lockwood A cinematic magnetic resonance imaging study of milk of magnesia laxative and an antiflatulent diet to reduce intrafraction prostate motion Int J Radiat Oncol Biol Phys 77 2010 1072 1078
40. J.D. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101
41. S.L. Gulliford, K. Fii, and R.C. Morgan Dose-volume constraints to reduce rectal side-effects from prostate radiotherapy: Evidence from MRC RT01 trial ISRCTN 47772397 Int J Radiat Oncol Biol Phys 76 2010 747 754
42. J.F. Fowler, P.M. Harari, and F. Leborgne Acute radiation reactions in oral and pharyngeal mucosa: Tolerable levels in altered fractionation schedules Radiother Oncol 69 2003 161 168
43. J.F. Fowler, R.J. Chappell, and M.A. Ritter Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
44. D.J. Brenner, A.A. Martinez, and G.K. Edmunson Direct evidence that prostate tumors show high radiosensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
45. M. Baumann, T. Holscher, and J. Denham Fractionation in prostate cancer - Is it time after all? (editorial) Radiother Oncol 96 2010 1 5
46. B.P. Falit, C.P. Gross, and K.B. Roberts Integrated prostate cancer centers and over-utilization of IMRT: A close look at fee-for-service medicine in radiation oncology Int J Radiat Oncol Biol Phys 76 2010 1285 1288